News | August 23, 2024
Lupin receives Health Canada approval for biosimilar Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Strong topline growth driven by solid performance across key brands.
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
